Menéndez T, Garay HE, Reyes O, Cruz Y, Coizeau E, Santiago NF, Chinea G, Cobas K, Caballero E, Morera V, Noda J, Carmenate T, Soria Y, Brown E, Martín A, Yero D, González S, Guillén GE

Language: Spanish
References: 15
Page: 113-115
PDF size: 78.08 Kb.

Text Extraction

The Gram-negative bacterium Neisseria meningitidis is an important cause of meningitis and septicemia worldwide. Meningococcal disease is a life threatening illness that may progress to death even after medical intervention. Approximately 500 000 - 1 000 000 cases of invasive meningococcal disease occur annually worldwide with a 10% mortality rate. Significant sequelae, including neurological damage, limb loss and hearing loss, occur in up to 20% of survivors. Meningococcal disease is more common among infants and young children (1). Prevention through vaccination remains the most effective approach to control invasive meningococcal disease.

REFERENCES

1. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9:285-98.

2. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-26.

3. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27 Suppl 2:B112-B116.

4. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195-207.

5. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981;127:1011-8.

6. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem. 1975; 250:1926-32.

7. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.

8. Shin JS, Lin JS, Anderson PW, Insel RA, Nahm MH. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infect Immun. 2001;69:3335-42.

9. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol. 1998;160:5028-36.

10. Pon RA, Lussier M, Yang QL, Jennings HJ. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J Exp Med.1997; 185:1929-38.

11. Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol. 1991;222:301-10.

12. Hoess R, Brinkmann U, Handel T, Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene. 1993;128:43-9.

13. Moe GR, Granoff DM. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int Rev Immunol. 2001;20:201-20.

14. Menéndez T, Santiago-Vispo NF, Cruz-Leal Y, Coizeau E, Garay H, Reyes O, et al. Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide. Int J Med Microbiol. 2011;301:16-25.

15. Garay H, Menendez T, Cruz-Leal Y, Coizeau E, Noda J, Morera V, et al. Study of various presentation forms for a peptide mimetic of Neisseria meningitidis serogroup B capsular polysaccharide. Bioconjug Chem. 2011;22:33-41.